Shark toob täna välja, et eilne suur langus tõstatab investoritele ette küsimuse, kas tegu ei ole mitte ostukohaga - seni on ju kõik sellised kukkumised kiiresti üles tagasi ostetud. Samas, täna võib olukord pisut teistsugune olla - nimelt olid eilse liikumise taga reaalsed negatiivsed uudised CFC-lt laenuturu kohta ning ka ettevõtete tulemused ei ole suutnud turge toetada. <br /><br />So the Bottom Fell Out -- Now What?<br />By Rev Shark<br />RealMoney.com Contributor<br />7/25/2007 8:05 AM EDT <br /><br /><br />The price one pays for pursuing any profession or calling is an intimate knowledge of its ugly side. <br />-- James Baldwin<br /><br />Although they don't happen that often, big, broad, ugly market days like yesterday are frequent enough that we shouldn't be terribly surprised by them. It is the nature of the market beast that it is going to turn on us now and then and make sure we don't forget who really is in charge. We are just along for the ride, and if we don't sufficiently respect the random nature of the beast, he is going to make sure we pay for our lack of respect. <br /><br />There is no sugarcoating how bad the action was yesterday was. Volume was very heavy, breadth very poor and the point loss was big. Few stocks escaped the carnage. If you were holding any longs at all, the great likelihood is that you took some hits. <br /><br />Rather than dwell on how poor the action was, we need to focus on the big question: where we go from here? Was this just a very big and ugly hiccup, or is this the beginning of the end? Are all those things the bears have been worried about finally going to start to matter? Is the consumer going to die and the stock market sputter as subprime woes and real estate problems continue to mount? <br /><br />As we consider that proposition, the first thing we need to contemplate is the big divergence in behavior between the indices. We have a rather peculiar situation where there is much better action in the DJIA and the Nasdaq than there is in the S&P 500 and small-cap indices. While the small-caps are back to levels we saw in April, the Nasdaq isn't even back to where it was two weeks ago. There are very notable technical differences in the patterns here, which would suggest that small-caps are in far worse shape than the big-cap technology stocks that dominate the Nasdaq 100 index. <br /><br />This morning with the strong report from Amazon.com (AMZN) and a huge move up, this divergence between big-cap tech and small-cap seems to be even more evident. Can that continue to play out, or will market problems broaden out and eventually infect the small group of stocks that have enjoyed great relative strength? <br /><br />In an ideal market, buying would filter down to small-caps as the big-cap leaders become relatively expensive. In theory, the rational thing to do is to look for a cheaper, small-cap alternative to a stock like AMZN that doesn't trade at a P/E of 100. But the market is peculiar in that way. <br /><br />Investors often find it more comfortable to continue to buy the stocks that are the most expensive and up the most. They will ignore stocks with good values while they continue to pile into the high-visibility names that everyone is very aware of. We have seen it for awhile now with Apple (AAPL) , Research in Motion (RIMM) , Baidu.com (BIDU) , MasterCard (MA) and so on. The technical conditions of the Nasdaq 100 and the small-cap indices suggest that it may continue that way. <br /><br />So now what? We have a good bounce setting up this morning as earnings reports are coming in better than expected. Given the intensity of the selling yesterday, a reflexive bounce should be expected, and a report like AMZN certainly helps the mood. <br /><br />The big question isn't whether we bounce a bit but whether we go straight back up and shrug off yesterday as an aberration. We have done just that quite often during this rally, and many folks will be anticipating that again, but this time the mood is a bit different. The selling was not only prompted by increased concern about lending but by the fact that high expectations for earnings were not being met. This is the first time in a while that market players are actually focusing on the possibility that a stock like Texas Instruments (TXN) or Intel (INTC) may have gotten a bit ahead of itself. <br /><br />My game plan at this point is to refine my list of favorite stocks and to watch for entry points to develop. A day like yesterday leaves many of them in technical limbo, and they need some time to find basis and to set up attractive entry points. If I know what stocks I like and watch them, I should be able to jump in when the odds become more favorable. <br /><br />We have a very strong bounce this morning, which makes any new buying at this point extremely difficult. Most overseas markets were down overnight but did not suffer nearly as badly as we did yesterday. Could it be that the U.S. market is simply not as important to the global economy as it once was? <br />-----------------------------<br />Ülespoole avanevad:<br /><br />Gapping up on strong earnings/guidance: AMZN +23.2%, ALXN +11.7%, ALGN +11.2%, CKSW +10.2%, BOBJ +8.7%, AEHR +8.4%, ILMN +8.2%, ANAD +7.5%, RFMD +6.5%, BA +3.1%... M&A: PRAI +9.4% (to be acquired by Genstar Capital for $30.50/share in cash), DADE -- stock is halted -- (to be acquired by Siemens for $77/share in cash, representing a 37% premium to last night's closing price)... Other news: EGLE +15.4% (agrees to acquire twenty-six Supramax vessels for $1.1 bln with approximately $1 bln of contracted revs), GGBM +9.6% (continued momentum).<br /><br />Allapoole avanevad:<br /><br />Gapping down on weak earnings/guidance: HOKU -15.8%, NTRI -12.8%, JOYG -9.7%, GLW -4.5%, PNRA -3.8%, STM -3.7%... Other news: GPCB -29.8% & SPPI -16.7% (FDA Oncologic Drugs Advisory Committee recommends that FDA wait for overall survival results from Satraplatin Phase 3 Trial), TGEN -23.9% (Inflammatory Arthritis Phase I/II Trial placed on clinical hold), SI -5.0% (to buy DADE for $77/share in cash).